FibroBiologics, Inc. Common Stock

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.